Correspondence 0001662774-24-000018 from Quince Therapeutics, Inc. (QNCX)
Quince Therapeutics, Inc.
Date: Dec. 23, 2024 · CIK: 0001662774 · Accession: 0001662774-24-000018
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-283897
Letter
Document
Quince Therapeutics, Inc.
611 Gateway Boulevard, Suite 273
South San Francisco, CA 94080
December 23, 2024
Via EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F. Street N.E.
Washington, D.C. 20549-3010
Attention: Daniel Crawford
RE: Quince Therapeutics, Inc.
Registration Statement on Form S-3
Filed December 18, 2024
File No. 333-283897
Ladies and Gentlemen:
Quince Therapeutics, Inc. (the “Registrant”) hereby requests that the U.S. Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 to become effective on Thursday, December 26, 2024, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable or at such later time as the Registrant may orally request via telephone call to the staff of the Commission. The Registrant hereby authorizes Gordon Ho of Cooley LLP, counsel to the Registrant, to make such request on its behalf.
Once the Registration Statement has been declared effective, please orally confirm that event with Gordon Ho of Cooley LLP, counsel to the Registrant, at (650) 843-5190.
[Signature Page Follows]
Very truly yours,
Quince Therapeutics, Inc.
Show Raw Text
CORRESP 1 filename1.htm Document Quince Therapeutics, Inc. 611 Gateway Boulevard, Suite 273 South San Francisco, CA 94080 December 23, 2024 Via EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F. Street N.E. Washington, D.C. 20549-3010 Attention: Daniel Crawford RE: Quince Therapeutics, Inc. Registration Statement on Form S-3 Filed December 18, 2024 File No. 333-283897 Ladies and Gentlemen: Quince Therapeutics, Inc. (the “Registrant”) hereby requests that the U.S. Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 to become effective on Thursday, December 26, 2024, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable or at such later time as the Registrant may orally request via telephone call to the staff of the Commission. The Registrant hereby authorizes Gordon Ho of Cooley LLP, counsel to the Registrant, to make such request on its behalf. Once the Registration Statement has been declared effective, please orally confirm that event with Gordon Ho of Cooley LLP, counsel to the Registrant, at (650) 843-5190. [Signature Page Follows] Very truly yours, Quince Therapeutics, Inc. By: /s/ Brendan Hannah Name: Brendan Hannah Title: Chief Business Officer and Chief Operating Officer cc: Gordon Ho, Cooley LLP